Huntington Disease: Clinical Features and Diagnosis
UptoDate Dec 2017, Oksana Suchowersky, 2017
Motor Changes in Presymptomatic Huntington Disease Gene Carriers
Arch Neurol 53:487-492, Siemers,E.,et al, 1996
Evidence-Based Guideline: Pharmacologic Treatment of Chorea in Huntington Disease
Neurol 79:597-603, Armstrong, M.J. & Miyasaki, J.M., 2012
Predictors of Diagnosis in Huntington Disease
Neurol 68:1710-1717, Langbehn,D.R.,et al, 2007
The Association of CAG Repeat Length with Clinical Progression in Huntington Disease
Neurol 66:1016-1020, Rosenblatt,A.,et al, 2006
Intoxication with Riluzole in Huntington's Diease
Neurol 57:1141-1143, Bodner,Th.,et al, 2001
Few Psychological Consequences of Presymptomatic Testing for Huntington Disease
Lancet 349:4, Bundey,S., 1997
CAG Repeat Number Governs the Development Rate of Pathology in Huntington's Disease
Ann Neurol 41:689-692, Penney,J.B.,et al, 1997
Relationship Between Trinucleotide Repeats and Neuropathological Changes in Huntington's Disease
Ann Neurol 39:132-136, Furtado,S.,et al, 1996
Trinucleotide Repeat Length and Clinical Progression in Huntington's Disease
Neurol 46:527-531, Brandt,J.,et al, 1996
Trinucleotide Repeat Length and Rate of Progression of Huntington's Disease
Ann Neurol 36:630-635, Illarioshkin,S.N.,et al, 1994
Molecular Genetics in Neurology
Ann Neurol 34:757-773, Martin,J.B., 1993
The Polymerase Chain Reaction:Application to Nervous System Disease
Ann Neurol 34:513-523, Darnell,R.B., 1993
The Psychological Consequences of Predictive Testing for Huntington's Disease
NEJM 327:1401-1405, 14491992., Wiggins,S.,et al, 1992
Tetrabenazine Therapy of Dystonia, Chorea, Tics, & Other Dyskinesias
Neurol 38:391-394, Jankovic,J.&Orman,J., 1988
Huntington's Disease Mortality in the United States
Neurol 38:769-772, Lanska,D.J.,et al, 1988
Huntington's Disease:Deterioration in Clinical State During Treatment with ACE Inhibitor
BMJ 294:1659-1660, Goldblatt,J.&Bryer,A., 1987